Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ranging from 18 to 80, both genders;~* Within 48 hours symptoms onset;~* According to TOAST classification, diagnosed to be large-artery atherosclerosis ischemic stroke, without history of stroke in the past three months;~* 5≤National Institutes of Health Stroke Scale (NIHSS) ≤25;~* Unilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis (rate of stenosis ranging from 50-99%);~* Sufficient bilateral temporal bone windows for insonation of the middle cerebral artery;~* Glasgow Coma Scale (GCS) ≥ 8;~* Willing to participate and sign the informed consent.~Exclusion Criteria:~* Patients who have received or plan to undergo intravascular interventional treatment/thrombolytic therapy;~* Coma or agitation, and can't cooperate to complete dCA;~* Has been given butylphthalide injection or capsules;~* Arrhythmia, anemia and hyperthyroidism which may influence the stability of cerebral blood flow diagnosed by two physicians by electrocardiogram and laboratory tests;~* Other intracranial diseases, including cerebral hemorrhage (primary or secondary), intracranial neoplasm, aneurysm, arteriovenous malformation, etc;~* Alanine transaminase (ALT) or glutamic-oxalacetic transaminase (AST) continued to rise more than 3 times the upper limit of normal , creatinine clearance rate\<30ml/min;~* Pre-stroke Modified Rankin Scale (mRS) score ≥ 2;~* Malignant neoplasm and expected lifetime \< 2 years;~* Pregnant and lactating women;~* Participating in other trials or has been participated in other trials in recent 3 months;~* Dementia and mental illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- butylphthalide(NBP) (Type: EXPERIMENTAL): Based on the standard medical care, 25mg of NBP injection, and 100ml of 0.9% saline; NBP capsule
- placebo (Type: PLACEBO_COMPARATOR): Based on the standard medical care, 100ml of 0.9% saline as the placebo; starch capsule as the placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).